Pfizer’s $6.05bn bet on oncology innovation: Inside the 3SBio SSGJ-707 licensing deal

Pfizer Inc. has entered into a global licensing agreement, excluding China, with Chinese biopharma leader 3SBio Inc. to commercialize SSGJ-707—a promising bispecific antibody targeting PD-1 and VEGF. Announced on May 19, 2025, this multi-billion-dollar deal grants Pfizer the exclusive rights to develop, manufacture, and distribute SSGJ-707 outside China. The antibody is currently undergoing clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.

Pfizer has committed to an upfront payment of $1.25 billion, with milestone-based payouts potentially reaching $4.8 billion. This brings the total deal value to $6.05 billion, not including double-digit tiered royalties on potential sales. Additionally, Pfizer will invest $100 million in 3SBio as part of a related equity subscription agreement, further solidifying its strategic interest in the partnership.

Why Is SSGJ-707 a Big Deal in Cancer Immunotherapy?

SSGJ-707 represents a next-generation bispecific antibody capable of blocking PD-1, a well-established immune checkpoint, while simultaneously inhibiting VEGF, a driver of tumor angiogenesis. This dual mechanism offers the potential for greater therapeutic synergy, particularly in solid tumors where resistance to single-target immunotherapies remains a challenge.

Initial clinical data from 3SBio’s Chinese trials suggest SSGJ-707 has a favorable safety and efficacy profile, prompting plans for a Phase 3 study launch later in 2025. The bispecific format, which merges checkpoint inhibition with anti-angiogenic effects, aligns with Pfizer’s strategic move into high-value, multifunctional biologics that can address resistance patterns and unlock new frontiers in immuno-oncology.

How Does This Fit Pfizer’s Broader Oncology Strategy?

This partnership dovetails with Pfizer’s broader commitment to oncology innovation, which now spans small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies. The company’s oncology division has already produced market-leading therapies in breast cancer, hematologic malignancies, and thoracic cancers, with ongoing R&D prioritizing combinatorial and mechanism-diversified approaches.

Pfizer will manufacture the drug substance in Sanford, North Carolina, and handle final formulation and packaging in McPherson, Kansas. This geographic dispersion reflects the company’s effort to establish a resilient supply chain architecture that supports rapid scale-up, global distribution, and reduced dependence on any single region for biologics manufacturing.

What Are the Financial Terms and Strategic Implications?

With a total deal value of over $6 billion, the agreement ranks among Pfizer’s most substantial licensing transactions. In contrast to traditional M&A, this partnership model allows Pfizer to mitigate upfront risk while still securing long-term pipeline control, with potential future commercialization rights for China left open as a strategic option.

For 3SBio, the infusion of $1.25 billion upfront plus equity investment provides deep funding to accelerate Chinese clinical development, including the Phase 3 study of SSGJ-707. For Pfizer, this agreement buys it optionality, global positioning, and access to a validated asset without the challenges of post-merger integration.

How Are the Markets and Analysts Reacting?

Pfizer’s stock (NYSE: PFE) closed at $23.32 on May 23, 2025, with a modest 1.28% daily gain. However, the broader picture remains subdued, with shares down approximately 19% over the past 12 months. Institutional ownership remains high at 68.36%, indicating continued interest from large funds. Data from MarketBeat suggests that institutional inflows over the past year totalled $13.75 billion, outweighing outflows of $11.51 billion—evidence of sustained, if cautious, buy-side support.

In contrast, 3SBio’s stock has been on a tear. The Hong Kong-listed firm saw its share price rise by 36% following the announcement, contributing to a year-to-date gain of 224.67%. Analyst sentiment has surged in tandem. Citi raised its target price to HKD 25 with a reiterated ‘Buy’ rating, while CICC boosted its target to HKD 21.10 and rated the stock ‘Outperform.’ The steep premium reflects confidence in SSGJ-707’s near-term milestone prospects and 3SBio’s platform credibility.

Why Is China Becoming Central to U.S. Biopharma Innovation?

The U.S.-China biotech corridor is witnessing increasing strategic alignment. U.S. pharmaceutical firms are now leveraging China’s maturing drug discovery and clinical development infrastructure to source pipeline-ready assets, while avoiding the full risk and complexity of acquisition-led growth.

This licensing model—where ex-China rights are bought by a U.S. firm while Chinese firms retain domestic commercialization—has been mirrored in deals by Gilead, Amgen, and Roche. Pfizer’s move builds on this trend, recognizing that Chinese biotech companies are now capable of generating globally competitive biologics that merit global scale-up.

Notably, Pfizer has secured an option to acquire China rights in the future, allowing it to expand if regulatory or political conditions improve. This built-in optionality exemplifies risk-aware deal structuring, allowing Pfizer to participate in Chinese commercial upside without being exposed upfront to domestic uncertainty.

Buy, Sell, or Hold? Investment Perspectives on Pfizer

Given its current trading range and the subdued reaction to this licensing announcement, Pfizer appears to be in a holding pattern with investors awaiting clinical proof points. The company’s share price underperformance reflects macro-level pressures—ranging from post-COVID product declines to pricing scrutiny and patent expiries.

That said, institutional flows remain moderately positive, and the company’s pipeline, including SSGJ-707, offers a medium-term catalyst portfolio. For most investors, a “Hold” recommendation is prudent, with upside potential linked to clinical readouts, regulatory filings, and future commercialization of bispecifics like SSGJ-707.

What’s Next for SSGJ-707 and Pfizer’s Oncology Ambitions?

Pending regulatory and shareholder approvals, the deal is expected to close in Q3 2025. Pfizer will assume development responsibilities outside China and may initiate parallel Phase 3 programs tailored to U.S. and European regulatory frameworks by 2026. If data hold up, initial filings could follow in 2027.

The commercial prospects of SSGJ-707 are especially promising in tumor types where PD-1 inhibitors like Keytruda or Opdivo have shown partial response, and where VEGF-driven angiogenesis plays a reinforcing role in tumor growth. The dual-mechanism approach could allow Pfizer to compete in multi-billion-dollar indications while avoiding direct head-to-head battles with entrenched mono-target therapies.

How Does This Compare with Pfizer’s Other Oncology Deals?

This licensing agreement ranks among Pfizer’s largest oncology transactions that do not involve full acquisitions. It recalls the company’s 2021 $2.26 billion acquisition of Trillium Therapeutics, which focused on CD47 immune checkpoint pathways in hematologic cancers. It also follows Pfizer’s 2022 partnership with Seagen Inc. for co-development of ADCs, which evolved into a $43 billion acquisition completed in 2023.

While those moves consolidated ownership over assets and platforms, the 3SBio transaction reflects a shift toward modular, cross-border licensing that limits integration overhead while maximizing innovation capture. Structurally, it mirrors similar collaborations seen across big pharma as companies opt for capital-efficient access to novel biologics.

Pfizer’s oncology blueprint is now clear: leverage a combination of acquisitions (Seagen), equity partnerships (3SBio), and milestone-rich licensing (SSGJ-707) to build a multi-modal immunotherapy portfolio that can compete across first-line and refractory settings. SSGJ-707 is not an isolated bet—it’s a puzzle piece in a much larger strategic mosaic.